Canaccord Genuity initiated coverage on Inventiva with a new price target
$IVA
Biotechnology: Pharmaceutical Preparations
Health Care
Canaccord Genuity initiated coverage of Inventiva with a rating of Buy and set a new price target of $12.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/12/2024 | $3.00 | Neutral | UBS |
| 10/27/2023 | $12.00 | Buy | Canaccord Genuity |
| 5/31/2023 | $11.00 | Buy | ROTH MKM |
| 5/19/2023 | Sell → Buy | Societe Generale | |
| 3/17/2023 | $27.00 | Buy | Stifel |
| 11/15/2022 | Buy → Sell | Societe Generale | |
| 11/22/2021 | $40.00 → $42.00 | Buy | HC Wainwright & Co. |
| 9/22/2021 | $38.00 → $40.00 | Buy | HC Wainwright & Co. |
Daix (France), New York City (New York, United States), December 17, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH"), and other diseases with significant unmet medical needs, today announced that Frédéric Cren, CEO and cofounder of Inventiva, has been invited to present a corporate overview, and will engage, with Inventiva's leadership team, in investor meetings at the upcoming 43rd Annual J.P. Morgan Annual Healthcare Conference, being held
Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024. Proceeds from the completed first tranche to be primarily used to advance Inventiva's Phase III, NATiV3 clinical trial evaluating lanifibranor in patients with MASH. Appointment of Mark Pruzanski as new Chairman of the Board of Directors and Srinivas Akkaraju as new member of the Board of Directors. Daix (France), New York City (New York, United States), December 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinica
Daix (France), New York City (New York, United States), December 11, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH"), and other diseases with significant unmet medical needs, today announced the results of the votes of its Combined Shareholders' Meeting. The Combined Shareholders' Meeting was held on Wednesday December 11, 2024, at 9 a.m. at Hôtel Oceania Le Jura, 14 avenue Foch, 21000 Dijon (France), under the chairmanship of Mr. Frédér
Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for both doses evaluated in the trial.Baseline characteristics of patients randomized in the main cohort of NATiV3 remain consistent with the characteristics of patients enrolled in the completed Phase IIb, NATIVE, clinical trial.Blinded analyses of patients in NATiV3 suggest a positive evolution of key biomarkers comparable to the Phase IIb, NATIVE, study results and that weight gain plateaus and stabilizes starting at week 24 to 36.Last patient randomization is anticipated in the first half of 20
Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at €0.01 million1, and long-term deposit at €9.0 million2 as of December 31, 2023, compared to €86.7 million, €1.0 million, and €0.7 million respectively, as of December 31, 2022 In September 2023, Inventiva entered into an exclusive licensing agreement with Hepalys to develop and commercialize lanifibranor in Japan and South Korea In January 2024, Inventiva received the second tranche of €25 million under the EIB loan agreement following its August 2023 financing of €35.7 million in gross proceeds, the upfront payment of $10 mill
Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2023 full-year financial results on Thursday, March 28, 2024. Inventiva's 2023 full-year financial results will be published on Wednesday, March 27, 2024 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, C
Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024. Proceeds from the completed first tranche to be primarily used to advance Inventiva's Phase III, NATiV3 clinical trial evaluating lanifibranor in patients with MASH. Appointment of Mark Pruzanski as new Chairman of the Board of Directors and Srinivas Akkaraju as new member of the Board of Directors. Daix (France), New York City (New York, United States), December 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinica
Inventiva secures €94.1 million of a multi-tranche equity financing of up to €348 million, subject to satisfaction of specified conditions, from both new and existing investors, and up to $30 million in milestone payments relating to equity financing pursuant to amendment to license and collaboration agreement with CTTQ.Proceeds from financing to be primarily used to advance Inventiva's Phase 3, NATiV3 clinical trial evaluating lanifibranor in patients with MASH. More than 1,100 patients randomized in the NATiV3 study evaluating lanifibranor for the treatment of noncirrhotic MASH, with completion of enrollment projected in 1H 2025.Appointment to the Board of Directors of Mark Pruzanski, MD,
Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH") and other diseases with significant unmet medical needs, today announced the nomination of Andre Turenne to its Board of Directors. Mr. Turenne's appointment will be submitted to the shareholders for ratification at the next general shareholder meeting. Frédéric Cren, Chairman, Chief Executive Officer, and cofounder of Inventiva: "We are extre
UBS initiated coverage of Inventiva with a rating of Neutral and set a new price target of $3.00
Canaccord Genuity initiated coverage of Inventiva with a rating of Buy and set a new price target of $12.00
ROTH MKM initiated coverage of Inventiva with a rating of Buy and set a new price target of $11.00
SCHEDULE 13D/A - Inventiva S.A. (0001756594) (Subject)
6-K - Inventiva S.A. (0001756594) (Filer)
6-K - Inventiva S.A. (0001756594) (Filer)
SC 13D/A - Inventiva S.A. (0001756594) (Subject)
SC 13D/A - Inventiva S.A. (0001756594) (Subject)
SC 13D/A - Inventiva S.A. (0001756594) (Subject)